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02ORIGINAL ARTICLEEffects of goal-directed crystalloid vs. colloid fluid therapy
on microcirculation during free flap surgery
A randomised clinical trial
Ildiko LaszloM, Agnes JanovszkyM, Andras Lovas, Viktoria Vargan, Nandor €Oveges, Tamas Tanczos,
Andras Mikor, Domonkos Trasy, Zoltan Loderer, Jozsef Piffko, Andrea Szabo and Zsolt MolnarBACKGROUNDMacro, and microcirculatory effects of crys-
talloids and colloids are difficult to compare, because inter-
ventions to achieve haemodynamic stability seldom follow
similar criteria.
OBJECTIVESOur aim was to compare the effects of crystal-
loids and colloids on the microcirculation during free flap
surgery when management was guided by detailed haemo-
dynamic assessment.
DESIGN A randomised, controlled clinical trial.
SETTINGS The investigation was performed at the Univer-
sity of Szeged, Hungary.
PATIENTS Patients undergoing maxillofacial tumour resec-
tion and free flap reconstruction were randomised into
groups treated with either intra-operative crystalloid (Ring-
erfundin, n¼15) or colloid (6% hydroxyethyl starch, HES,
n¼15) solutions.
INTERVENTIONS Macrohaemodynamics were monitored
by a noncalibrated device (PulsioFlex-PULSION). Central
venous oxygen saturation, venous-to-arterial PCO2-gap, lac-
tate levels and urine output were measured hourly. Mainte-
nance fluid was Ringerfundin (1ml kg1 h1), and a
multimodal, individualised, approach-based algorithm was
applied to guide haemodynamic support. Hypovolaemiaht © European Society of Anaesthesiology. Una
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tively. The microcirculatory effects were assessed by laser-
Doppler flowmetry (PeriFlux 5000 LDPM), with the probe
placed on the flap and on a control area. Measurements were
performed after the flap was prepared, then 1 and 12h later.
MAIN OUTCOME MEASURES The primary end-point was
microcirculatory perfusion as determined by laser-Doppler
flowmetry.
RESULTS There was no difference between the groups
regarding patient characteristics. Both groups remained
haemodynamically stable throughout due to the use of
approximately a 1.5 times higher total fluid volume in the
Ringerfundin group than in the HES group: meanSD:
2581986 and 1803497) ml, respectively,
(P¼0.011). There was no significant difference in the micro-
circulatory blood flow between the groups.
CONCLUSIONOur results showed that when fluid manage-
ment was guided by detailed haemodynamic assessment,
more crystalloid than colloid was needed to maintain hae-
modynamic stability, but there was no difference between the
effects of crystalloids and colloids on the microcirculation.
TRIAL REGISTRATION ClinicalTrials.gov NCT03288051.
Published online 30 May 2019Introduction
Inappropriate haemodynamic management during major
surgery may lead to hypoperfusion or fluid overload, both
of which are accompanied by a significant risk of impairedpostoperative outcome.1 The same holds true for unnec-
essary use of vasoactive medications2 and blood transfu-
sions.3,4 In reducing such adverse effects, advanced
haemodynamic monitoring-based management has
a strong pathophysiological rationale and, indeed,uthorized reproduction of this article is prohibited.
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tive management has been shown to improve outcomes
in high-risk surgery in several studies.5,6 These
trials showed that high-risk patients, especially those
undergoing bowel surgery, benefited from this approach,
with reduced postoperative complications and increased
survival.
In addition to haemodynamic management, the type of
fluid used may also have an important effect on outcome.
The crystalloid-colloid debate has a long history, and
most studies conclude that colloids seem to be superior to
crystalloids as far as microcirculatory perfusion was con-
cerned.7 Many surgeons and anaesthetists share this
belief, despite the fact that none of the clinical trials
that investigated this issue used detailed haemodynamic
assessment.7 Furthermore, the advantages of colloid solu-
tions for the microcirculation have been shown in clinical
studies applying goal-directed therapy, without inclusion
of crystalloid group as a control.8,9 Therefore, one cannot
exclude the possibility that the observed benefit of
colloids on the microcirculation was due to better global
haemodynamic conditions achieved by the better vol-
ume-replacement ratio of colloids (as compared with
crystalloids), and not due to their better microcirculatory
properties per se.
Therefore, our aim was to perform a randomised clinical
trial to examine the effects of intra-operative crystalloid
and colloid fluid replacement on microcirculatory
perfusion in patients undergoing free flap surgery for
maxillofacial malignancy; fluid boluses for intra-
operative hypovolemia were guided by detailed haemo-
dynamic monitoring.
Materials and methods
Patient selection
This randomised, controlled study (Ethical Committee
No. 44/2014) was undertaken between April 2014 and
February 2018 and was approved by the Regional and
Institutional Human Medical Biological Research
Ethics Committee, University of Szeged, Hungary on
28 April 2014. The investigation was performed at
the University of Szeged. The study was registered at
ClinicalTrials.gov with the registration number:
NCT03288051. Written informed consent was obtained
from all participants.
Adult patients of both sexes undergoing radical forearm
free flap surgery were recruited. Exclusion criteria
included vulnerable individuals as defined in ISO
14155 : 2011, pregnant or lactating women, and end-stage
oral cancer. The progress of participants through the
study is depicted in Fig. 1.
Patients were randomised either to a crystalloid group
(Ringerfundin; B. Braun Melsungen, Germany) or a
colloid group [hydroxyethyl starch (HES), Voluven 6%;
Fresenius Kabi Deutschland, Germany], using enveloperight © European Society of Anaesthesiology. Ublock-randomisation in blocks of fifteen. Patient enrol-
ment, sequence generation and assignment to interven-
tions were performed by a responsible investigator. Only
the patients were blind to group allocation.
Intra-operative protocol
Patients received routine anaesthetic management. In
addition to standard monitoring, a radial artery catheter
was inserted under local anaesthesia for invasive blood
pressure monitoring. This arterial line was also connected
to a noncalibrated haemodynamic monitor (ProAQT;
PULSION Medical Systems SE, Munich, Germany).
Anaesthesia was induced with 1 to 3mgkg1 propofol
[Propofol (1%), Fresenius Kabi Deutschland, Germany],
0.6mgkg1 rocuronium (Esmeron, MSD Pharma
Hungary, Hungary), and for analgesia, morphine (Morfina
Jacopo Monico, Italy) was used. Anaesthesia was main-
tained with sevoflurane with the minimum alveolar con-
centration maintained around 1.3 vol%. Patients were
ventilated with an 8ml kg1 tidal volume, in pressure
control mode, in order to have a reasonable effect on
pulse pressure variation (PPV).5,10 During the operation,
core temperature was measured by rectal thermometer.
Maintenance fluid was Ringerfundin 1ml kg1 h1.
After induction of anaesthesia, a central venous catheter
was inserted into the right internal jugular or the right
subclavian vein based on the requirements of the surgical
approach. Haemodynamic assessment during the opera-
tion was based on a multimodal concept shown in Fig. 2.
This included elements of the model that had been
applied and reported in a recent multicentre clinical trial,
in which our institute also participated.6
In brief, fluid responsiveness was defined as PPV at least
10%, but this this did not mean that fluid was given
immediately: fluid administration was determined by a
complex, multimodal algorithm, depicted in Fig. 2. In
cases when fluid loading was indicated, a bolus of 250ml
of Ringerfundin or HES, as determined by randomisa-
tion, was administered within 15min. The aim was to
maintain cardiac index (CI) above 2.5 lmin1m2. If CI
was low, and our haemodynamic model indicated that
contractility had to be improved, then dobutamine
(Dobutamine Hexal, Sandoz Hungaria, Hungary) was
administered starting at a rate of 5hg kg1min1. In
the case of a drop in blood pressure, as indicated by a
mean arterial pressure of 65mmHg or less or at least 20%
drop as compared with baseline data, after excluding
hypovolemia, or myocardial depression, norepinephrine
was started as a continuous infusion.
Global haemodynamic assessment was complemented
with measuring hourly urine output and arterial and
central venous blood gas analysis. Parameters included
in the haemodynamic decision algorithm were central
venous oxygen saturation (ScvO2), central venous-to-
arterial CO2-gap (dCO2), arterial lactate, HCO3 andnauthorized reproduction of this article is prohibited.
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Fig. 1
Assessed for eligibility 
Excluded (n = 7) 
Not meeting inclusion criteria (n  =  5) 
Declined to participate (n = 2) 
Other reasons (n = 0)  
Analysed (n = 15) 
 Excluded from analysis (n = 0)
Lost to follow-up (n = 0)
Discontinued intervention (n = 0) 
Allocated to RF (n = 15)
 Received allocated intervention (n = 15) 
 Did not receive allocated (n = 0)
Lost to follow-up (n = 0) 
Discontinued intervention (n =  0)
Allocated to HES (n = 15) 
 Received allocated intervention (n = 15)
 Did not receive allocated intervention (n = 0) 
Analysed (n = 15) 
Excluded from analysis (n = 0)
Allocation
Analysis
Follow-up 
Randomised (n = 30)
Enrolment 
Flow chart according to the CONSORT (Consolidated Standards of Reporting Trials) statement showing the progress of participants throughout
the study.pH. Normal values for these parameters were considered
as ScvO2: 70 to 80%, dCO2 of 6mmHg or less, HCO3: 20
to 24mmol l1, pH: 7.35 to 7.45. Arterial and central
venous samples were taken at the same time hourly, or
anytime in between, when a decision had to be supported
in order to commence therapy. This approach was
aimed at helping to individualise treatment, rather than
following a preset target value.
Data were recorded after instrumentation at baseline
(T0), at incision (Ti) and then hourly until the end of
the surgery (Tes) and 24 h after T0 (T24).
Laser-Doppler flowmetry
All flaps were monitored with noninvasive laser-Doppler
flowmetry (PeriFlux 5000 LDPM; Perimed, Ja¨rfa¨lla,
Sweden) intra-operatively, and postoperatively. A probe
with a standard fibre separation of 0.25mm, and a 780 nm
wavelength laser was used. The depth of the measure-
ments was 0.5 to 1mm. Results are expressed as perfusionight © European Society of Anaesthesiology. Una
Eur J Anaesthesiol 2019; 36:592–604units. The first measurements were taken after the flap
was prepared (Rbsl), then 1 h after reperfusion and con-
tinued hourly for up to 12 h (R1–R12). The probe was
placed and fixed in a position in the centre of the forearm
flap skin island. The skin in the deltoid region provided
the control site. At both places, measurements were taken
after active warming of the skin, at 358C and 448C. Data
were recorded for more than 2min at each measurement
point. Quantitative assessment of the recording periods
was performed off-line.
Postoperative and ICU protocol
All patients were monitored in the ICU until they were
discharged to the Maxillofacial Surgery ward. Patients
received standard ICU care according to our institutional
protocols.
Data analysis and statistics
For statistical analysis, Statistical Program for Social
Sciences version 23.0 for Windows (SPSS, Chicago,uthorized reproduction of this article is prohibited.
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Fig. 2
PPV>10%
CI≥ 2.5 l min−1m−2 <2.5 l min−1m−2
MAP
<65 mmHg≥ 65 mmHg
FluidObserve
MAP
<65 mmHg≥ 65 mmHg
Inotropes+/−Fluid Fluid+/−Inotropes
CI <2.5 l min−1m−2≥ 2.5 l min−1m−2
MAP
Inotropes
MAP
Vasopressor
≤10%
Intermittent assessment of hourly taken blood gas samples (ScvO2, PCO2 gap, lactate, Hgb) and urine output
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Observe Vasopressor
(a) Haemodynamic assessment and interventions. CI, cardiac index; Hgb, haemoglobin; MAP, mean arterial pressure; PCO2 gap, central venous-to-
arterial PCO2-gap; PPV, pulse pressure variability; ScvO2, central venous oxygen saturation; SVV, stroke volume variation. (b) Measurements
and recordings: T0, baseline; Ti, incision; Tes, end of surgery; T24, day one. Rbsl, baseline (Laser-Doppler after flap was prepared); R1, one hour after
R2–12, hourly.Illinois, USA) was used, and P value less than 0.05
was considered as significant. Data are presented as
meanSD or median [IQR]. For testing normal distri-
bution, the Shapiro–Wilk test was used. Independent
samples were tested by independent samples t-test or
Mann–Whitney U test, as appropriate. Changes in
repeated measures throughout the experiment were
tested by two-way repeated measures analysis of variance
(ANOVA) with Bonferroni post hoc comparisons. Cate-
gorical data were compared using x2 tests. The Type I
error probability associated with this test of the null
hypothesis is 0.05.
The study’s primary end-point was the difference in the
perfusion units as determined by laser-Doppler at R12. On
the basis of preliminary results, for a study to have 80%
power to show a significant difference in perfusion units at
R12, when the standardised difference (clinically signifi-
cant difference/standard deviation) worked out to be 0.9,
required a minimum of 30 patients in total (15 per group).
Results
There was no difference in the demographics, as sum-
marised in Table 1. Complete flap failure occurred on fiveright © European Society of Anaesthesiology. Uoccasions (one in the Ringerfundin, four in the HES
group, P¼ 0.142).
Macrohaemodynamic effects of fluid resuscitation
Patients remainedhaemodynamically stable throughout the
observation period in both groups (Table 2). PPV was in
general higher in the Ringerfundin group, which became
significant at T3. CI also showed the same pattern in both
groups, with significantly higher values in HES group at T1.
At T0, the systemic vascular resistance index values were
significantly elevated in the Ringerfundin group. Several
other parameters showed changes during the experiment,
without any significant differences between the groups.
Intra-operative total urine output reached similar values in
the HES and Ringerfundin-treated groups [355.0 (166.4)
ml and 477.3 (212.5) ml, respectively, P¼ 0.090]. Creati-
nine values as measured 24h after surgery were not differ-
ent between the groups either [HES, 76 (19) mmol l1;
Ringerfundin, 71 (26) mmol l1, P¼ 0.505].
Respiratory parameters
Respiratory data are summarised in Table 3. Overall, all
parameters showed similar values in both groups.nauthorized reproduction of this article is prohibited.
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Table 1 Demographic variables of patients in the crystalloid (Ringerfundin) to and colloid (hydroxyethyl starch) to treated groups
Demography RF (nU15) HES (nU15) P
Female/Male 5/10 3/12 0.409
Age (years) 6411 6210 0.680
Height (cm) 170.69.0 168.87.2 0.550
Weight (kg) 72.0 [60.0 to 83.0] 62.0 [57.0 to 81.0] 0.539
BMI (kgm2) 24.4 [21.6 to 27.8] 24.0 [19.6 to 31.6] 0.775
Scores
APACHE II (point) 13.5 [9.5 to 15.25] 14.0 [7.75 to 16.0] 0.946
APACHE MR (%) 17.66.8 16.78.3 0.731
ASA 1 (n) 3 0 0.250
ASA 2 (n) 9 10
ASA 3 (n) 3 5
Procedures
Duration of operation (min) 354.359.4 342.479.1 0.644
Duration of ischemia (min) 66.913.1 67.919.3 0.869
LOS
ICU (days) 2 [2 to 3] 2 [2 to 2] 0.389
Hospital (days) 9 [7 to 13] 10 [8 to 15] 0.325
Organ support on ICU
Mechanical ventilation (days) 1 [1 to 1] 1 [0 to 1] 0.595
Vasopressor (days) 0 [0 to 1] 1 [0 to 1] 0.683
Dialysis (therapy) 1 0
Data are presented as meanSD, median [IQR] and n. APACHE II, Acute Physiology and Chronic Health Evaluation II; APACHE MR, Acute Physiology and Chronic
Health Evaluation Mortality Rate; ASA, American Society of Anaesthesiologists’ classification; LOS, length of stay.Although end-tidal CO2 was significantly elevated in the
HES group at T0 and Ti, it still stayed within the normal
range.
Blood gas parameters
All parameters remained within the physiological normal
range throughout the observation period and, although
there were certain statistically significant differences
observed, these can be regarded as clinically nonrelevant
(Table 4). Haemoglobin concentration in the HES group
showed a significant decrease over time, without the need
for blood transfusion.
Oxygen consumption and oxygen delivery were more or
less stable throughout the study and followed similar
patterns in both groups. Oxygen extraction changed
accordingly with nomajor difference between the groups.
Total amount of intra-operative and ICU medications
As listed in Table 5, the Ringerfundin group required
significantly more boluses and greater total amounts of
fluid. Blood loss did not differ between the groups.
During surgery, the Ringerfundin group was given 1.5
times more boluses of fluid than the HES group. There
were no significant differences in the postoperative
period.
Nearly half of the patients required vasopressors
(Ringerfundin, n¼ 8; HES, n¼ 7) and inotropic support
(Ringerfundin, n¼ 6; HES, n¼ 7), without significant
difference in the required doses between the groups.
Total amount of anaesthetic and analgesic agents was
similar in both groups.ight © European Society of Anaesthesiology. Una
Eur J Anaesthesiol 2019; 36:592–604Microcirculation and corresponding
macrohaemodynamics
As evidenced by laser-Doppler flowmetry, baseline per-
fusion values were similar at the flap areas (in situ, before
harvesting) and at the control sites in both groups (at 358C
and 448C) (Figs. 3 and 4). During reperfusion, however,
significantly higher tissue perfusion values were observed
at the free flap sites in both groups than those observed at
baseline or at the control areas (at corresponding time-
points) at 358C (Fig. 3). A significant difference in the
perfusion of the free flaps areas was observed only in the
ninth hour of reperfusion between the groups when
perfusion values appeared to be higher in the Ringer-
fundin group. Heat provocation (to 448C) induced
increases in tissue perfusion only at the control areas,
whereas this effect was missing in the flaps during reper-
fusion in both groups (Fig. 4). In the macrohaemody-
namic values, a significant difference was found in the
DBP (Dia) and PPV during the second hour of reperfu-
sion (R2), but these changes were not accompanied by
significant changes in microcirculatory perfusion at any
sites. Changes in macrohaemodynamic parameters at
different reperfusion measurement points varied accord-
ing to the surgical section (Table 6).
Discussion
This randomised clinical trial aimed to investigate the
effects of crystalloid vs. colloid fluid replacement to treat
intra-operative hypovolemia during free flap surgery on
global haemodynamic parameters and microcirculation.
It was found that patients in the crystalloid group
required more fluid than patients in the colloid group,
without any significant difference in the macrocirculation
and microcirculation. To detect hypovolaemia, advanceduthorized reproduction of this article is prohibited.
Copyright © European Society of Anaesthesiology. Unauthorized reproduction of this article is prohibited.
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Eur J Anaesthesiol 2019; 36:592–604haemodynamic monitoring was applied in order to mini-
mise the possibility of diagnostic errors and administer
fluid boluses only when hypovolaemia was strongly sup-
ported by physiological parameters.
Crystalloids vs. colloids – macrocirculation
The crystalloid-colloid controversy has been in focus for
several decades. Over the last 15 years, several large,
multicentre, randomised clinical trials were published
mainly in critically ill patients. Most of these compared
crystalloids with HES and concluded that there is no
difference, or they observed worse outcome in the HES
group.11–13 On the basis of these results, current guide-
lines recommend strongly against the use of HES espe-
cially in septic patients.14 Although the investigation of
renal function was not the goal of this study, the finding
that there was no difference in urine output, and serum
creatinine levels remained in the normal range in both
groups, with no patient requiring renal replacement
therapy in the HES group provides support that there
is no current evidence that HES causes renal insuffi-
ciency in the peri-operative period.15
Ernest Starling’s three-compartment model, describing
the distribution of total body water, forms the physiolog-
ical rationale for using colloids in clinical practice.
According to this hypothesis, colloids (i.e. similar to
albumin) should stay within the intravascular space,
while crystalloids should be distributed in the extracel-
lular (intravascular and interstitial) space. Therefore,
theoretically, one unit of blood loss can be replaced by
three to four units of crystalloid or one unit of colloid
solution.16 However, several clinical trials, including
thousands of critically ill patients, seem to disprove this
principle, as we do not see this major difference in the
required volume of crystalloids vs. colloids to stabilise
these patients. On one hand, this discrepancy between
physiology and clinical observations can be explained by
the destruction of the glycocalyx in critically ill, septic
patients, which impairs the semipermeable function of
the endothelium; hence, colloids can escape into the
interstitial space in substantial quantities.17 On the other
hand, none of these trials used detailed haemodynamic
monitoring. In the current study, detailed haemodynamic
evaluation was performed in order to detect hypovolae-
mia adequately. This resulted in higher amount of crys-
talloid infusion in the Ringerfundin group than in the
HES group but, despite less colloid being administered,
haemodilution was only significant in the HES group,
thus indicating a better volume replacement effect.
Strictly speaking, Starling’s principle – suggesting that
3-4 times more crystalloid than colloid is required for the
same volume replacement effect-, could not be con-
firmed in our trial. To some extent, these results seem
to differ from the findings of our recent experiment in a
bleeding-resuscitation pig model: fluids followed the
Starling’s distribution and this was explained by normaluthorized reproduction of this article is prohibited.
Copyright © European Society of Anaesthesiology. Unauthorized reproduction of this article is prohibited.
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Table 5 Total amount of intra-operative medications in the
crystalloid (Ringerfundin) and colloid (hydroxyethyl starch) groups
Fluid balance RF (nU15) HES (nU15) P
IOP Total Maintenance
fluid (RF ml)
731.2621.5 653.2229.3 0.654
IOP Boluses (ml) 1850.0900.4 1150.0580.9 0.017M
IOP Boluses (events) 7.43.6 4.62.3 0.017M
IOP Total fluid (ml) 2581.2986.2 1803.2497.9 0.011M
IOP Blood loss (ml) 150.0
[100.0 to 225.0]
250.0
[100.0 to 400.0]
0.346
Vasopressors, Inotropes
IOP Noradrenalin (mg) 10.0 [0.0 to 781.4] 0.0 [0.0 to 450.0] 0.870
IOP Dobutamine (mg) 0.0 [0.0 to 35.5] 0.0 [0.0 to 79.5] 0.967
Anaesthetics, Analgesics
IOP Propofol (mg) 172.062.7 190.762.3 0.420
IOP Morphine (mg) 15.0
[13.0 to 20.0]
20.0
[12.0 to 20.0]
0.512
IOP Fentanyl (mg) 100.0
[0.0 to 100.0]
100.0
[100.0 to 200.0]
0.202
IOP Rocuronium (mg) 132.050.6 139.041.2 0.681
Data are meanSD or median [IQR]. MP<0.05 significant difference between
the groups.
Eur J Anaesthesiol 2019; 36:592–604levels of glycocalyx degradation products.18 Unfortu-
nately, we did not have a chance to measure glycocalyx
degradation products in the present clinical study. Nev-
ertheless, our results provide further data to support the
premise that during fluid therapy, to achieve similar
haemodynamic goals, less colloid than crystalloid is
required, therefore resuscitation could be completed
faster with colloids.
Crystalloids vs. colloids – microcirculation
Correction of systemic haemodynamics should be effec-
tive in ameliorating regional and microcirculatory perfu-
sion.19 The assumption that colloids, compared with
crystalloids, have superior effects on the microcirculatory
blood flow underestimates the importance of haemody-
namic stabilisation, and gives all the credit to the better
pharmacological properties of colloids.8,20 Furthermore,
most of the studies in the field did not measure cardiac
output and its derivatives. Therefore, one cannot exclude
that the beneficial effects of colloids on the microcircu-
lation were due to their better volume expansion, which
caused an increased cardiac output, hence better regional
blood flow, rather than the features of the colloid mole-
cules per se.
In the present trial, microcirculation (as examined by
laser-Doppler flowmetry) showed no clinically important
difference between the crystalloid and colloid groups
either when the probe was placed on the control area
or on the flap itself. Because the free flaps lose their
innervation (including sympathetic innervation) during
harvesting, significantly higher perfusion values can be
observed at these sites during reperfusion.21 Heat-
induced vasodilation, which requires both intact innerva-
tion (mostly mediated by c-afferents) and endothelial
function,22 is apparently lost in the free flaps duringuthorized reproduction of this article is prohibited.
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Fig. 3
Tissue perfusion at heating to 35 °C
Time (hr)
1
0
50
100
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P
U
Control area - RF
Reperfusion
Baseline
Flap
(in situ)
Control area - HES
Flap - RF
Flap - HES
Perfusion is expressed as the ratio of the perfused units at 448C/PU without heating (i.e. at original temperature). The figure shows tissue perfusion
on heating to 358C in the forearm flap and at the control area (skin at the deltoid region) in the crystalloid (RF) and colloid (HES) treated patients at
different time-points of the study. Recordings were taken when the flap was prepared (Rbsl), 1 h after reperfusion and continued hourly for up to 12h.
Data are presented as meanSD. P<0.05 significant difference between groups. yP<0.05 vs. Rbsl.reperfusion in both treatment groups. This latter reac-
tion, however, is present in the control areas, and reaches
similar values in both groups. These results suggest that
haemodynamic stability probably has a higher impact on
regional microcirculation than the type of infusion fluid
used to achieve this state.8,9 Furthermore, intravenously
administered vasopressors may affect denervated vessels
via the endothelial nitric oxide system,23,24 but our results
suggest that norepinephrine can be used safely and does
not harm the flap when its administration is controlled by
appropriate haemodynamic assessment.
Although all flaps survived the study period, we observed
that four flaps failed in the HES group and one in the
Ringerfundin group within the first 10 days. However,
in three cases, flap failure occurred most probably due to
surgical complications, but our sample size is too small to
draw any firm conclusions.
Haemodynamic assessment
It appears that most of the clinical trials comparing the
effect of crystalloids and colloids share the common
feature of inappropriate haemodynamic assessment.
The administration of intravenous (i.v.) fluids was
mainly based on the subjective decision of the clini-
cians,11,13,25–27 or on parameters such as heart rate,12right © European Society of Anaesthesiology. Ublood pressure,11,13,28 central venous pressure,11,13,28
urine output,11–13,25,28 lactate levels12 or central venous
oxygen saturation.11,13,28 Measurements of cardiac out-
put, stroke volume, stroke volume/PPV were typically
not included.
In the current study detailed, multimodal haemodynamic
evaluation was performed in order to detect haemody-
namic ‘instability’, or more precisely to detect changes in
haemodynamics, which would indicate a requirement for
intervention. Furthermore, instead of targeting treatment
according to fixed values (often seen in recent clinical
trials), we applied a multimodal concept, including regu-
lar blood gas (both arterial and central venous) analyses.
About 40% of patients needed inotropic support during
surgery. This is in accordance with recent results showing
that whenever advanced haemodynamic monitoring was
used intra-operatively, patients required not only fluid
and vasopressors but also positive inotropic support.5
Another important issue to note is that, according to
the haemodynamic assessment, patients’ intra-operative
fluid requirements varied from a minimum of 500ml to
almost 3.5 l, indicating a huge individual variability and
emphasising the need for advanced haemodynamic mon-
itoring to guide fluid management in selected cases.nauthorized reproduction of this article is prohibited.
Eur J Anaesthesiol 2019; 36:592–604
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Fig. 4
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Perfusion is expressed as the ratio of the perfused units at 448C/PU without heating (i.e. at original temperature). The figure shows the effects on
perfusion at the control site (skin at the deltoid region) and in the forearm flap in the crystalloid (RF) and colloid (HES) treated patients at different
time-points. Recordings were taken when the flap was prepared (Rbsl), 1 h after reperfusion and continued hourly for up to 12h. Data are presented
as meanSD. P<0.05 significant difference between groups. yP<0.05 vs. Rbsl.Limitations
Our study has several limitations. It was a single-centre
trial with a relatively small sample size and long-term
effects could not be evaluated. Examination of the effects
of HES on renal function would have been an important
issue, but this was not among the aims of the present
study. Haemodynamic monitoring was performed with
a noncalibrated device. It has been reported that the
accuracy and trending ability of noncalibrated devices
are moderate or even poor when compared with gold
standard technologies applying thermodilution measure-
ments.29,30 However, such results were mainly reported
in critically ill patients, a very different population from
that in the present trial. Although awareness and pain can
exert a profound effect on haemodynamic variables,
depth of anaesthesia monitoring was not used. However,
in addition to clinical signs, continuous measurement of
end-tidal sevoflurane was performed, and we aimed to
keep the minimal alveolar concentration above 1.3 to
achieve adequate depth of anaesthesia. As regards the
type of fluids chosen, comparing Ringerfundin with a
balanced HES-solution (Volulyte rather than Voluven)
could have been a better choice. Finally, if glycocalyxight © European Society of Anaesthesiology. Una
Eur J Anaesthesiol 2019; 36:592–604degradation products could have been measured, it could
have provided an important explanation for the observed
difference in the amount of fluid required after crystalloid
and colloid treatments.Conclusion
In this randomised clinical trial performed during free flap
surgery, we found that compared with colloid, higher
amounts of crystalloid were needed to achieve similar
haemodynamic stability. There was no difference
between the crystalloid and colloid groups as far as hae-
modynamic parameters were concerned nor was there a
difference in flapperfusion either.Our results indicate that
in patients without relevant blood losses and relatively low
infused fluid volumes, when haemodynamic stability is
maintainedwith the aid of detailed haemodynamic assess-
ment, there is no measurable impact from the type of
infusion fluid on free flap microcirculation.Acknowledgements relating to this article
Assistance with the study: we would like to thank the assistants,
medical students and staff at the Institute of Surgical Research, theuthorized reproduction of this article is prohibited.
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